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Abstract
Background: Sinularin isolated from the cultured soft coral Sinularia flexibilis has been reported to exert potent
cytotoxic effects against particular types of cancer. This study was carried out to investigate the cytotoxic effects in
sinularin-treated human hepatocellular carcinoma cells, HepG2, and to subsequently explore the underlying molecular
mechanisms.
Methods: TheMTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl- tetrazolium bromide) method was used to evaluate the
cytotoxicity of sinularin on HepG2 and Hep3B cell lines. Furthermore, the cell cycle distribution assay, apoptosis assay,
and western blot analysis in vitro were used to explore the possible mechanisms of action.
Results: From the results of our study, cell viability was obviously inhibited by sinularin in a dose-dependent manner.
In addition, our results suggested that sinularin triggered DNA damage and subsequently induced cell cycle G2/M arrest
associated with up-regulation of p-ATM (Ser(1981)), p-Chk2 (Tyr(68)), p-cdc2 (Tyr(15)), and p53 coupled with increased
expression of downstream proteins p21 and down-regulation of p-cdc25 (Ser(216)). Moreover, the results of
the apoptosis assay and western blot analysis indicated that the cytotoxic activity could be related to mitochondrial
apoptosis, characterized by decrease of Bcl-2 expression, disruption of mitochondrial membrane potential, and
sequential activation of caspases and Poly (ADP-ribose) polymerase (PARP).
Conclusions: This study reveals for the first time the anti-HCC activities of sinularin, the active compound isolated from
the cultured soft coral Sinularia flexibilis. We believe that our results warrant further evaluation of sinularin as
a new anti-HCC chemotherapeutic agent.
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Background
Hepatocellular carcinoma (HCC) is a primary liver
malignancy and the second highest cause of cancer-
related death in the world [1]. Without specific treat-
ment, HCC carries a dismal prognosis and the reported
5-year survival rate is as low as approximately 10% [2].
The incidence of HCC is highly related to endemic
hepatitis viral infections such as HBV, HCV, or HDV.
Currently, there are only a few strategies for HCC
treatment – radical treatments such as surgical resection
and orthotopic liver transplantation (OLT), radiation
therapy, and chemotherapy. However, most HCC patients’
liver cancers are in middle to advanced stages upon
diagnosis. As a result, they cannot be selected as candi-
dates for these radical treatments. Thus, anticancer drugs
are a more feasible option for treating advanced HCC.
Sorafenib, a serine-threonine kinase inhibitor, is currently
the only approved systematic drug for anti-HCC. Unfortu-
nately, the efficacy of sorafenib is limited, and some
patients are intolerant [3]. Therefore, more effective thera-
peutic strategies for HCC are needed.
Sinularin is a natural product isolated from cultured
soft coral, Sinularia flexibilis, and since 1977 has been
shown to possess antineoplastic activity against human
epidermoid carcinoma and P388 lymphocytic leukemia
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[4]. Despite its significant anti-cancer activities, very few
studies have focused on sinularin research. To date, two
studies reported that sinularin exhibited anti-tumor
activities in human gastric carcinoma and melanoma
cells [5, 6]. In addition to anti-tumor effects, sinularin
has been shown to inhibit the production of inflamma-
tory mediators such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) stimulated by
lipopolysaccharide (LPS) [7]. As a result, sinularin is a
bioactive compound with multiple functions in tumor
suppression and immunomodulation.
The mechanisms of anti-cancer activity exerted by
sinularin are not clear and require further investigation.
To our knowledge, there are currently no scientific
reports focused on the antitumor effects of sinularin
against human liver cancer cells. Thus, in this study, we
utilized sinularin to evaluate its cytotoxic effects on
human hepatocellular carcinoma cells and investigate
the mechanistic pathways of cancer cell death.
Methods
Chemicals
The marine natural compound, sinularin, was isolated
from the soft coral S. flexibilis as described [5] and
kindly provided by Dr. Jui-Hsin Su (National Museum
of Marine Biology & Aquarium, Pingtung, Taiwan);
sorafenib was purchased from Cayman Chemical
(Ann Arbor, MI USA). Sinularin and sorafenib were
dissolved in dimethyl sulfoxide (DMSO; Sigma-
Aldrich, St. Louis, MO USA) at 100 mM as stock
solution for in vitro assays. Henceforth, DMSO and
sorafenib were used as vehicle control and positive
control, respectively.
Cell lines and culture
The human hepatocellular carcinoma cell lines,
HepG2 and Hep3B, were purchased from American
Type Culture Collection (ATCC®) (Manassas, VA
USA). The growth medium is DMEM with 10% (v/v)
fetal bovine serum (FBS), streptomycin (100 μg/mL)
and penicillin (100 U/ml) (Gibco/BRL, Gran Island,
NY USA). Cells were cultured in incubators with 5%
CO2 at 37 °C.
MTT assay
Cell viability was monitored by the MTT colorimetric
assay (BioVision, Milpitas, CA USA). Briefly, 200 μL of
MTT (0.5 mg/mL) was added to each well and incu-
bated for 4 h at 37 °C after removing the culture super-
natants. MTT crystals were dissolved by DMSO and the
absorbance was measured at 540 nm wavelength with an
ELISA microplate reader (Tecan Sunrise, San Jose, CA
USA). All MTT assays were performed in 96-well plates
and repeated at least three times.
Cell cycle assay
Sinularin- or sorafenib- treated cells were harvested,
washed with PBS, and fixed with 70% ethanol at −20 °C
overnight. The fixed cells were stained by propidium
iodide (PI; Sigma-Aldrich, St. Louis, MO USA) contain-
ing RNase A (Sigma-Aldrich, St. Louis, MO USA) for
30 min in the dark at room temperature. The cells
were then analyzed by an AccuriTM C5 cytometer
(BD Biosciences, San Jose, CA USA). Data were further
analyzed by C6 Accuri system software (BD Biosciences,
San Jose, CA USA).
Annexin V-FITC/PI staining assay
The Annexin V-FITC/PI staining assay was performed
using the FITC Annexin V Apoptosis Detection Kit
(BioVision, Milpitas, CA USA) in accordance with
manufacturer’s instructions. In brief, sinularin-treated
cells were trypsinized and gently washed with cold PBS
twice followed by resuspension in binding buffer. Equal
volumes of Annexin V-FITC and propidium iodide were
added to stain cells for 10 min at room temperature in
the dark prior to determining the percentage of apop-
totic cells with an AccuriTM C5 cytometer.
Measurement of mitochondrial membrane potential
(MMP)
HepG2 cells treated with sinularin for 24 h were trypsi-
nized, washed with PBS, and resuspended with culture
medium followed by staining with JC-1 solution (10 ng/μL)
(Life Invitrogen, Carlsbad, CA USA) for 10 min at 37 °C.
Changes in mitochondrial membrane potential were then
examined by an AccuriTM C5 cytometer.
Western blotting
Cells were harvested with lysis buffer after treatments at
the indicated time points. BCA Protein Assay Reagent
(Thermo Fisher Scientific, Waltham, MA USA) was
utilized to measure the protein concentrations before
performing SDS-polyacrylamide gel electrophoresis. Pro-
teins were then transferred to PVDF membranes for
subsequent antibody hybridization. The membranes
were blocked with 5% non-fat milk at room temperature
for 1 h and blotted with primary antibody at 4 °C for
overnight incubation, followed by secondary antibodies
conjugated with horseradish peroxidase (HRP) (Jackson
Laboratory, Bar Harbor, ME USA) at 4 °C overnight.
The immunoactive bands were detected with an
enhanced chemiluminescence (ECL) system and developed
using the LAS3000 system (Fujifilm, Valhalla, NY USA). In
this study, the primary antibodies obtained from Cell
Signaling Technology Inc. (Beverly, MA USA) were anti--
phospho-cdc25-ser-216, anti-cdc25, anti-cyclin B1, anti-
p53, anti-p21, anti-cleaved-caspase-3, anti-BCL-2, anti-
cleaved-caspase-8, anti-cleaved-caspase-9, anti-cleaved-
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PARP, anti-Bax, anti-phospho-ATM-ser-1981, anti-ATM,
anti-CHK-2, anti-ATR-ser-428, anti-ATR anti-phospho-
CHK-2-Thr-68, anti-phospho-CHK-1-ser-345, anti-CHK-1
antibodies, from Epitomics (Burlingame, CA USA)
were anti-cdc2-Tyr-15 and anti-cdc2 antibodies, from
GeneTex (Sann Antonio, TX USA) were anti-cyclin
B1 and anti-GAPDH antibodies, and from Millpore
(Billerica, MA USA) were anti-p-H2A.X and anti-
GAPDH antibodies.
Statistical analysis
The results were expressed as the mean ± SD. All
statistical analyses were performed with the GraphPad
Prism software package version 5.0. Experimental data
grouped by one variable were evaluated by one-way
analysis of variable followed by Tukey’s test. Statistical
significance is considered if P value is less than 0.05
(P < 0.05).
Results
Sinularin reduced the viability of human liver cancer cells
The cytotoxic effect of sinularin on the viability of liver
cancer cell lines was determined by MTT assay. We
treated two human liver cancer cell lines (HepG2 and
Hep3B) with sinularin or sorafenib, a positive control, at
different concentrations for 24 h. As shown in Fig. 1,
both sinularin and sorafenib induced cytotoxicity in
human liver cancer cell lines in a dose-dependent
manner. Notably, these two liver cell lines exhibited
different sensitivities to sinularin and sorafenib; the in-
hibitory concentration 50% (IC50) values of sinularin and
sorafenib to HepG2 were 17.5 ± 6.7 μM and 9.4 ± 2.3 μM
respectively, while the IC50 values to Hep3B were 43.2 ±
8.1 μM and 33.9 ± 8.6 μM respectively. The results indi-
cated that sinularin has a similar cytotoxic effect as
sorafenib on both HepG2 and Hep3B. Also, the HepG2
cell line was highly sensitive to sinularin treatments;
thus, we selected HepG2 to perform further analysis and
evaluation of the cytotoxic potency of sinularin.
Sinularin induced G2/M arrest and apoptosis in HepG2
cells
To further understand the functional mechanisms of
sinularin in inhibiting cell growth, we studied the cell
cycle profiles of HepG2 cells after sinularin treatment.
Fig. 2a shows that 24-h treatment with sinularin caused
high populations of HepG2 cells arrested in G2/M
checkpoint at 25 μM concentrations. The accumulation
of the sub-G1 phase population at 50 μM group indi-
cated that high doses of sinularin led to massive cell
death within 24 h. We subsequently analyzed the cell
cycle profiles of HepG2 cells treated with 50 μM sinu-
larin at 6, 12, and 24 h and found that high concentra-
tions of sinularin induced significant accumulation of
HepG2 cells in the G2/M phase after 6- and 12-h treat-
ments (Fig. 2b); thus, the sub-G1 phase population in-
creased at 24 h post-treatment.
We further tested whether sinularin elicited apop-
totic cell death in HepG2 cells at 24 h of sinularin
treatment by staining phosphatidylserine with annexin
V conjugated with fluorescein isothiocyanate (FITC)
and DNA with propidium iodide (PI). As shown in Fig. 2c,
the percentages of early apoptotic (annexin V+/PI− in
lower-right quadrants) and late apoptotic or necrotic
HepG2 cells (annexin V+/PI+ in upper- right quad-
rants) were higher in a dose-dependent manner
compared to the DMSO control, suggesting that sinu-
larin increased cell death and caused the G2/M arrest
in HepG2 cells.
Fig. 1 Analysis of cell viabilities in HCC cell lines. Percentages of cell
viabilities of (a) HepG2 and (b) Hep3B cells after treating with sinularin
or sorafenib at different concentrations for 24 h. Cell viabilities
were plotted and represented as means ± SD. All data presented
are representatives of three independent experiments with similar
results. Significant differences from DMSO treated control group are
indicated by **p < 0.01, ***p < 0.001
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Sinularin affected the expressions of G2/M corresponding
proteins in HepG2 cells
Next, we examined the G2/M-related protein expres-
sions involved in cell cycle progression following
sinularin treatment. The results showed that the levels
of p53, and p21 increased remarkably after 12-h treat-
ment with sinularin. Of note, the expression of
phospho-Cdc25C (Ser-216) was dose-dependently
suppressed, whereas phospho-Cdc2 (Tyr-15) was posi-
tively augmented at the same time point (Fig. 3). These
data strongly indicated that sinularin could induce G2/M
Fig. 2 Cell cycle distributions of HepG2 cells with sinularin treatments.
a Cell cycle analysis of sinularin-treated cells. HepG2 cells were treated
with the indicated concentrations of sinularin for 24 h, or (b) treated
with 50 μM of sinularin for 6, 12, and 24 h. Cell cycle distributions were
determined by propidium iodide (PI) staining and flow cytometry analysis.
Data are representative of three independent experiments with
similar results. c Analysis of sinularin-induced apoptosis in HepG2 cells
at indicated concentrations for 24 h. Phosphatidylserine externalization
and DNA integrity were determined by FITC-annexin-V and PI, respectively.
The lower-right quadrant (annexin-V+/PI−) represents early apoptosis, while
the upper-right quadrant (annexin V+/PI+) indicates late apoptosis
and necrosis. The means ± SD of the experimental triplicates are
presented in the bar graph at the bottom. All data presented
are representatives of three independent experiments with similar results.
Significant differences from DMSO treated control group are indicated
by **p< 0.01, ***p< 0.001
Fig. 3 Sinularin affected the cell cycle regulatory proteins in HePG2
cells. HepG2 cells were treated with different dosages of sinularin for
12 h and western blotting was performed to quantify the expression
levels of cell cycle regulatory proteins. GAPDH expressions were
measured as internal controls to show equal protein loading. The data
presented are representatives of three independent experiments with
similar results
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arrest by altering the expressions of G2/M corre-
sponding proteins.
Sinularin altered mitochondrial membrane potential
(Δψm)
Changes of mitochondrial membrane potential are
considered indicators of cellular insults or stressors.
Mitochondrial membrane potentials in apoptotic cells
are low due to depolarization which can be quantified by
cationic fluorescent dyes such as DiOC6 or JC-1 [8, 9].
Here we utilized JC-1 to measure the mitochondrial
membrane potential by flow cytometry after sinularin
treatment. As shown in Fig. 4, green fluorescent signals
increased in HepG2 cells after sinularin treatment in a
concentration-dependent manner after 24 h, suggesting
that treatment with sinularin led to apoptosis in HepG2
cells and that mitochondrial dysfunction could be in-
volved in sinularin-induced apoptosis.
Sinularin regulated the expressions of apoptotic proteins
in HepG2 cells
The mitochondrial apoptotic pathway involves the activa-
tion of apoptosome-associated initiator caspases, such as
caspases 8 and 9. Initiator caspases, in turn, activate
downstream caspase 3, which subsequently induces cleav-
age of Poly (ADP-ribose) polymerase (PARP) [10–12].
Thus, we performed western blotting to elucidate the
relationships among the apoptotic proteins in HepG2 cells
after 24 h of exposure to sinularin. The data clearly
demonstrated that sinularin treatment up-regulated the
expressions of cleaved caspases 8, 9, 3, and PAPR (Fig. 5a).
Besides, proteins in the B-cell lymphoma-2 (Bcl-2) family
Fig. 4 Sinularin induced MMP reduction in HepG2 cells. HepG2 cells were treated with different dosages of sinularin for 24 h. Mitochondrial
membrane potential (Δψm) was determined by JC-1 fluorescent dye staining and flow cytometry analysis. The means ± SD of the experimental
triplicates were presented in the bar graph at the bottom. All data presented are representatives of three independent experiments with similar
results. Significant differences from DMSO treated control group are indicated by **p < 0.01, ***p < 0.001
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play distinguished roles in apoptosis. For example, Bcl-2
inhibits apoptosis whereas Bax has opposite function
[13, 14]. We examined the protein expressions of Bcl-2
and Bax and found that Bcl-2 expression levels were
decreased, whereas Bax was increased after sinularin treat-
ment (Fig. 5b). These data revealed that sinularin induced
apoptosis in HepG2 cells by regulating the apoptotic
proteins associated with mitochondrial pathway.
Sinularin activated ATM/Chk2-medicated DNA damages
We investigated whether sinularin caused DNA damage
in HepG2 cells, which would in turn initiate the apoptosis
pathway to achieve its anti-tumor activity. We analyzed
the expression levels of DNA damage signaling molecules,
including ataxia telangiectasia mutated (ATM), ATM and
Rad3-related (ATR), checkpoint kinase 1 and 2 (Chk1/2),
and phosphorylated histone H2A.X (p-H2A.X). As shown
in Fig. 6, the levels of phosphorylated ATM on Ser-1981
and phosphorylated Chk2 on Thr-68, a downstream target
of ATM, along with p-H2A.X, were significantly increased
in a concentration-dependent manner after exposure to
sinularin but not phospho-ATR (Ser-428) or phospho-
Chk1 (Ser-345). These findings suggest that the induction
of DNA damage by sinularin caused cytotoxicity in
HepG2 cells.
Discussion
Cytotoxic chemotherapy has been a mainstay treatment
for advanced HCC and the chemotherapeutic agents
trigger apoptosis in HCC by inducing massive DNA
damage, which fail to undergo productive DNA repair
[15]. It is also well-known that HCC exhibits resistance
to chemotherapy or radiotherapy and recent studies
have revealed that the emerging resistance of HCC to
conventional therapies resulted from the induction of
resistance-associated protein 2 and anti-apoptotic Bcl-2
[16, 17]. Furthermore, HCC’s resistance to multiple
drugs greatly diminishes the effectiveness of chemotherapy
treatments. As a result, it is necessary to develop second
Fig. 5 Sinularin regulated the protein levels of apoptosis in HepG2
cells. a and b Cell lysates of HepG2 cells were collected after sinularin
treatments at 12.5, 25, and 50 μM for 24 h and western blotting was
used to determine the protein expression levels. GAPDH expressions
were measured as internal controls to show equal protein loading. The
data presented are representatives of three independent experiments
with similar results
Fig. 6 Sinularin triggered DNA damage responses in HepG2 cells.
HepG2 cells were treated with sinularin at 12.5, 25, and 50 μM for 24 h
followed by western blotting to measure the DNA damage related
proteins, phospho and non-phospho ATM, ATR, Chk1, Chk2, and H2A.X.
GAPDH expressions were measured as internal controls to show equal
protein loading. The data presented are representatives of three
independent experiments with similar results
Chung et al. BMC Complementary and Alternative Medicine  (2017) 17:62 Page 6 of 8
line chemotherapeutic agents. Although the apoptosis
mechanisms induced by sinularin require further investiga-
tion, we clearly demonstrated in this study that sinularin
caused PARP-mediated apoptosis of HCC via activation of
cascade caspases such as caspase 3, 8, and 9 as well as by
repressing Bcl-2 expression and activating Bax, which is
subsequently down-regulated in HCC (Fig. 5).
DNA damage induced by anti-cancer drugs can initiate
p53-dependent and p53-independent pathways to block
cells at the G2/M checkpoint and from entry into
mitosis by which drugs can exert their anti-cancer
effects [18]. For the p53-depedent pathway, several tran-
scriptional targets of p53, including p21 can down-
regulate the expression of cdc2 and cyclin B1 in addition
to directly inactivating cdc2 protein. Hence, inactive
cdc2/cyclin B1 can’t further activate cdc25 which is
essential for mitosis [19]. On the other hand, the p53-in-
dependent pathway of G2/M arrest is involved with
DNA repair proteins such as the kinases ATM and ATR,
which can activate downstream Chk1 and Chk2 kinase,
respectively, and cause cdc25 to anchor in the cytoplasm
[20–22]. Sinularin, in this study, was shown to not only
elevate p53 and p21 expression levels (p53-dependent)
but also to increase the protein levels of phosphorylated
ATM/Chk2 (p53-indenpent), but not Chk1. Our results
indicated that sinularin induced the DNA damage and
caused G2/M arrest in HCC via both pathways. These
results also explained the reason why sinularin seems to
exhibit higher cytotoxicity to HepG2 with wild-type p53
than to Hep3B cells, which is a p53 null cell line (Fig. 1).
Given DNA damage usually comes along with oxida-
tive stress and that reactive oxygen species (ROS) could
be involved in leading to the mitochondria outer mem-
brane permeabilization (MOMP) [23, 24], it is possible
that sinularin induced oxidative DNA damage as well.
We measured the ROS levels by using the fluorescent
probe DCFDA after sinularin treatment with HCC, but
there were no significant changes observed between
sinularin-treated cells and untreated cells, suggesting
that sinularin-induced DNA damage and cytotoxicity is
not associated with the generation of ROS in human
HepG2 cells (data not shown).
Sorafenib, a multiple kinase inhibitor, is the only
approved chemotherapeutic agent for treating advanced
HCC. Sorafenib exhibits its tumor suppression effects in
cell growth, angiogenesis, and can be applied toward
macrovascular invasion and extra hepatic metastasis
[25]. A recent study showed that sorafenib induced more
apoptosis in HepG2 than Hep3B cells due to higher
expression levels of microRNA, miR-181a, in Hep3B
cells, suggesting miR-181a contributes to the drug resist-
ance of HCC [26]. In response to the anticancer drug-re-
sistance of HCC, some second-line anticancer drugs
have been evaluated in combination with sorafenib
treatment. For example, an epidermal growth factor
receptor (EGFR)-related tyrosine kinase enzyme inhibi-
tor, Erlotinib, was applied for treatment of advanced
HCC in a phase-III trial [27]. In this study, not only did
we provide a new respect for cytotoxic chemothera-
peutic strategies by applying a natural marine com-
pound in treating HCC, but out data also revealed
that the targets of sinularin are distinguished from
sorafenib which makes sinularin a good candidate as
a second-line antineoplastic drug.
Conclusions
In our study, we have shown that sinularin can effect-
ively inhibit the proliferation of human hepatocellular
carcinoma HepG2 cells by increasing G2/M cell cycle
arrest, inducing apoptosis, and activating DNA damage
responses, thus contributing to the antitumor activity of
sinularin. Overall, our results demonstrated that sinularin
might be a potential candidate in HCC chemoprevention
and chemotherapy.
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